The purpose of the BabyCOVE Study is to assess the safety and effectiveness of an investigational vaccine against SARS-CoV-2 in infants 12–26 weeks old.
The BabyCOVE Study will be conducted in 2 parts:
All participants will receive 2 doses, 8 weeks apart.
Sites are located in the cities/states identified with the red pin:
Participation in this clinical trial lasts up to 15 months and includes up to 8 in-person visits and up to 2 virtual visits with the clinical trial staff.
Participants will receive 2 vaccinations, approximately 8 weeks apart (Day 1 and Day 57).
At in-person visits, the clinical trial staff will perform a physical exam, sometimes including a nasal swab and blood draw.
Participants’ parents will be asked to use an eDiary app on their personal smartphone or a provided device to answer prompts and report any symptoms their child experiences.
Insurance is not needed to join this clinical trial, and compensation for trial-related time may be available.